RESEARCH HIGHLIGHTS
ANZUP ANNUAL REPORT 2019
GRANTS AND AWARDS Infrastructure Grants Funds provided by Cancer Australia to support ANZUP infrastructure are managed by the University of Sydney NHMRC Clinical Trials Centre and therefore not reported in the financial accounts of ANZUP unless transferred in support of specific expenses incurred by ANZUP. Grants contributing to ANZUP infrastructure costs during the 2018-19 period are outlined below.
Funding Cancer Australia Infrastructure Grant: 1 July 2013 to 31 August 2018- $2,300,000 awarded to ANZUP and our collaborator on the grant NHMRC CTC. During this reporting period $150,000 was transferred to ANZUP and was reported in the Annual Accounts.
Research Grants Funds provided by Cancer Australia, the National Health and Medical Research Council and other bodies in support of trial coordination are also managed by the University of Sydney NHRMC Clinical Trials Centre and therefore are not reported in the financial accounts of ANZUP. Grants awarded to ANZUP Cancer Trials Group during this reporting period are listed below: BCG+MMC: A randomised phase III trial adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non– muscle-invasive bladder cancer. Funding Cancer Australia $457,143.17: 2013-2018. No funds were was transferred to ANZUP during the reporting period. Phase III Accelerated BEP (Cancer Australia and Cancer Council Australia): A randomised trial of accelerated versus standard BEP chemotherapy for intermediate and poorrisk advanced germ cell tumours. Funding Cancer Australia $363,583, Cancer Council Australia $222,000:2013-2018. ENZAMET: A randomised phase III trial of Enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer. Funding Astellas $17,131,966: 2014-2020 During this reporting period $738,607 was transferred to ANZUP and was reported in the Annual Accounts. ENZARAD: A randomised phase III trial of Enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer. Funding Astellas, $11,946,080: 2014-2020. During this reporting period $85,400 was transferred to ANZUP and was reported in the Annual Accounts.
Pain Free TRUS B: A placebo-controlled, randomised trial of methoxyflurane to reduce the discomfort of prostate biopsy. Funding Cancer Australia $354,764.00 Prostate Cancer Foundation of Australia $242,331.00: 2015-2018. During this reporting period, no funds were transferred to ANZUP. BL.12: A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients with Advanced Urothelial Cancer Progressing on or after a Platinum Containing Regimen. Funding NCIC Clinical Trials Group $1,384,662.00, Specialised Therapeutics $250,000.00: 20152018. During this period no funds were transferred to ANZUP. PCR MIB Pembrolizumab with ChemoRadiotherapy as treatment for Muscle Invasive Bladder Cancer. Grant funding support from Merck Sharp & Dohme (Australia), $455,800.00 to conduct the study, anticipated to take up to 5 years. $109, 270 was received during the reporting period, and is reported in the annual accounts. TIGER: A randomised Phase 3 trial comparing conventionaldose chemotherapy using paclitaxel, ifosfamide, citplasin (TIP) with high-dose chemotherapy using mobilising paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumours (TIGER). Funding Movember $261,997. During this period $119,500 was received and is reported in the Annual Accounts. KEYPAD: A phase II trial using denosumab and pembrolizumab in clear cell renal carcinoma. Funding by Merck Sharpe Dohme and Amgen ($2,454,925). During this reporting period $429,791 was received and is reported in the annual accounts. UNICAB: During this reporting period $150,000 was received and reported in the annual accounts. UNISoN: A phase II sequential cohort trial of single agent nivolumab, then combination ipilimumab + nivolumab in metastatic or unresectable non-clear cell renal cell carcinoma. Funding from Bristol Myers Squibb ($). During this reporting period $340,000 was received and is reported in the annual accounts. TheraP: An open label, randomised, stratified, 2-arm, multicentre phase 2 trial of Lu-PSMA617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer. Funding received from PCFA and Endocyte ($2,525,000). During this reporting period $900,000 was received and reported in the annual accounts. All funds received are utilised for the conduct of trial activity as performed by third party organisations under the direction of ANZUP.
41
